# Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

> **NCT00425373** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1474 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Valsartan + amlodipine 40/2.5 mg
- **DRUG:** Valsartan + amlodipine 40/5 mg
- **DRUG:** Valsartan + amlodipine 80/2.5 mg
- **DRUG:** Valsartan + amlodipine 80/5 mg
- **DRUG:** Valsartan 40 mg
- **DRUG:** Valsartan 80 mg
- **DRUG:** Amlodipine 2.5 mg
- **DRUG:** Amlodipine 5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00425373
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 1474 (ACTUAL)
- **Last updated:** 2011-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425373, "Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00425373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*